Selank

Mechanism of action

Selank is a 7-amino-acid synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP) derived from tuftsin — an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) generated by enzymatic cleavage of the Fc fragment of IgG by the spleen-derived enzyme leukokininase. The native tuftsin sequence is rapidly degraded by serum peptidases (half-life of minutes); Selank's C-terminal Pro-Gly-Pro tripeptide extension confers proteolytic stability through the same molecular strategy used for Semax, retaining the bioactive tuftsin pharmacophore while extending duration of action. The molecular mechanism of Selank is multifactorial and less precisely characterised than the more directly receptor-targeted research peptides. Three principal mechanistic pathways have been documented in pre-clinical and clinical work. First, modulation of enkephalinase (neutral endopeptidase, neprilysin) activity: Selank inhibits the enzymatic breakdown of endogenous enkephalins, raising central enkephalin tone and producing downstream effects on the µ-opioid system that contribute to the anxiolytic phenotype. The enkephalinase-modulating activity is the principal mechanistic strand distinguishing Selank from Semax and from conventional benzodiazepine anxiolytics. Second, modulation of GABAergic neurotransmission: Selank produces effects on GABA-A receptor function and central GABA tone that are partially distinct from benzodiazepine mechanisms — the published characterisation suggests Selank does not directly bind the benzodiazepine GABA-A site but produces functional GABA-A pathway effects through upstream modulation. Third, modulation of serotonergic neurotransmission, particularly through effects on 5-HT-1A receptor signalling, contributing to the broader anxiolytic-and-mood-stabilising pharmacology. Downstream effects of these mechanisms include modulation of BDNF and several other neurotrophin expression patterns in the hippocampus and prefrontal cortex (effects smaller than Semax's BDNF/NGF upregulation but in the same direction), modulation of T-cell function and inflammatory cytokine balance (reflecting the immunomodulatory ancestry of the native tuftsin sequence), and behavioural anxiolytic effects in standard rodent anxiety models (elevated plus maze, light/dark box, conditioned fear paradigms). The anxiolytic phenotype is consistently reported as 'non-sedating' — unlike benzodiazepines, Selank does not produce cognitive impairment, sedation, or psychomotor slowing at anxiolytic doses, and there is no documented tolerance, dependence, or withdrawal syndrome with chronic use. The immunomodulatory ancestry of the native tuftsin sequence is reflected in Selank's pleiotropic effects beyond the primary anxiolytic activity. Modest effects on T-cell function, natural killer cell activity, and inflammatory cytokine production have been documented and contribute to research interest in Selank for inflammation-related anxiety and depression phenotypes. The lack of clear primary-receptor target distinguishes Selank pharmacologically from receptor-defined compounds (semaglutide, tirzepatide) and places it in the category of multi-mechanism peptides whose pharmacology is best characterised by integrated downstream effects rather than by single-receptor binding. As with Semax, the intranasal delivery route is mechanistically essential — Selank's negligible blood-brain barrier penetration after peripheral administration means intranasal delivery exploiting the olfactory and trigeminal nerve pathways is the only practical CNS-targeting administration approach. Intranasal pharmacokinetic studies have confirmed CSF concentrations 10-30 fold above equivalent IV doses, with sustained hippocampal and prefrontal cortex exposure supporting the 4-12 hour functional effect duration.

Russian randomised controlled trials demonstrated Selank non-inferiority to benzodiazepine comparator medazepam in generalised anxiety disorder with materially better tolerability — no sedation, no cognitive impairment, no tolerance/dependence development over study duration. This established Selank as the prototype 'non-benzodiazepine anxiolytic peptide' and the principal clinical differentiator supporting Russian regulatory registration.

— Notable finding

Research history

Selank was developed by the Russian Institute of Molecular Genetics (Moscow) — the same institute that developed Semax — in the 1990s, with the goal of producing a stable tuftsin analogue with anxiolytic rather than the nootropic profile of Semax. The molecular design originated from systematic analysis of tuftsin's behavioural pharmacology, with the Pro-Gly-Pro stabilising extension applied successfully to retain the bioactive tuftsin sequence while extending duration of action — paralleling the medicinal-chemistry approach used for Semax. Clinical development in Russia established Selank as a registered prescription anxiolytic medicine, with regulatory approval for generalised anxiety disorder and several related anxiety-spectrum conditions. The Russian clinical development included randomised controlled trials in generalised anxiety disorder demonstrating non-inferiority versus standard benzodiazepine comparators (typically medazepam), with the favourable side-effect profile (no sedation, no cognitive impairment, no tolerance/dependence) being the principal differentiator supporting registration. The compound has been studied in animal anxiety, depression, and cognitive models across the 1990s to 2020s, with a substantial pre-clinical publication record. Independent verification of Russian clinical efficacy claims by Western research groups has been limited but generally supportive of the underlying mechanism. The published Western-language literature on Selank is smaller than the Russian-language literature, reflecting the geopolitical complexity of Russian pharmaceutical-research translation. Selank has not been pursued for FDA, EMA, or MHRA marketing authorisation. The off-patent nature of the molecule, the absence of a Western sponsor, and the broader complexity of translating Russian anxiolytic-medicine regulatory frameworks to Western standards have prevented progression toward Western licensure. The compound exists in Russia as a registered prescription anxiolytic medicine and in Western jurisdictions including the UK as an unlicensed research-chemical and grey-market substance. In the research-chemical-community context, Selank has gained substantial visibility since the late 2010s as the prototype 'anxiolytic peptide' alongside Semax as the prototype 'nootropic peptide'. The combined intranasal 'Semax + Selank' protocol has become a standard nootropic-anxiolytic research-chemical-community framework, exploiting the complementary mechanisms of the two compounds.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Selank has a substantial Russian clinical-use safety dataset accumulated through anxiolytic registration and post-marketing surveillance. The adverse-event profile reported in Russian clinical experience is favourable: mild and transient adverse effects predominate, with nasal irritation (mild stinging, occasional runny nose) being the most common; occasional mild fatigue; rare reports of transient gastrointestinal upset. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented. The principal safety feature distinguishing Selank from benzodiazepine comparators is the absence of sedation, cognitive impairment, tolerance, dependence, and withdrawal syndrome. Russian clinical practice has used chronic Selank dosing (months) without surfacing the dependence and withdrawal phenomena that limit chronic benzodiazepine use, and without the cognitive-impairment and psychomotor-slowing effects that complicate benzodiazepine pharmacology. This favourable comparison is the principal mechanistic argument for Selank over benzodiazepines in chronic anxiety management. Western pre-clinical safety data are limited but consistent with the Russian clinical experience. Acute and sub-chronic rodent toxicology studies have not identified dose-limiting organ-specific toxicity at doses materially above the human clinical equivalent. The intranasal route limits systemic exposure to a fraction of central exposure, further reducing off-target peripheral safety concerns. Theoretical safety considerations centre on the immunomodulatory ancestry of the tuftsin sequence. Chronic Selank dosing could theoretically affect T-cell function, NK cell activity, and inflammatory cytokine production in clinically meaningful ways, particularly in immunocompromised subjects or in subjects with autoimmune disease. The Russian clinical experience has not surfaced significant signals in these domains, but the chronic-dosing record is not equivalent to a formal Western Phase III/IV regulatory dataset. No serious acute adverse events have been documented at research-protocol doses. The acute safety profile is favourable; the chronic-dosing record from Russian clinical use is the principal long-term safety dataset.

UK regulatory status

Selank is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any Western jurisdiction. It is a registered prescription anxiolytic medicine in Russia; this registration does not confer UK regulatory status. Selank is not a controlled substance under the Misuse of Drugs Act 1971. Possession of research-grade material for bona fide in-vitro and animal research is generally unrestricted in the UK. Supply or administration of Selank to humans outside an authorised UK clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — the Russian registration does not authorise UK supply or use. Selank is not currently on the WADA Prohibited List. Its anxiolytic and modest nootropic mechanisms do not currently fall within any WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, Selank work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit. As with Semax, UK individuals occasionally obtain Selank via personal import from Russian or Eastern European pharmacies. The Border Force and MHRA position on personal-import unlicensed medicines is restrictive in principle though enforcement intensity is variable; researchers should consult appropriate regulatory channels.

Frequently asked questions